造血癌症微环境的结构与功能：聚焦慢性淋巴细胞白血病
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.
作者信息
Fecteau Jessi-F, Kipps Thomas J
机构信息
Rebecca and John Moores Cancer Center, UCSD, La Jolla, CA 92093-0820, USA.
出版信息
Front Biosci (Schol Ed). 2012 Jan 1;4(1):61-73. doi: 10.2741/s251.
Abstract
Chronic Lymphocytic Leukemia (CLL) is a B cell malignancy characterized by the accumulation of mature monoclonal CD5-positive B cells in the blood, secondary lymphoid tissues, and marrow. The infiltration of CLL cells in lymphoid tissues is a key element of disease pathogenesis. It is in such tissues that are found the microenvironments that provide CLL cells protection from spontaneous and/or drug-induced apoptosis. CLL cells actively shape their microenvironment by producing cytokines and chemokines, and by subverting normal accessory cells to promote leukemia-cell survival, proliferation, and escape from immune detection. In this review, we discuss how CLL cells disrupt the niches required for normal hematopoiesis or immune function and subvert normal cells in the microenvironment to support neoplastic cell growth and survival.
摘要
慢性淋巴细胞白血病（CLL）是一种B细胞恶性肿瘤，其特征是成熟的单克隆CD5阳性B细胞在血液、二级淋巴组织和骨髓中积聚。CLL细胞浸润淋巴组织是疾病发病机制的关键因素。正是在这些组织中发现了为CLL细胞提供保护使其免受自发和/或药物诱导凋亡的微环境。CLL细胞通过产生细胞因子和趋化因子，以及颠覆正常辅助细胞来促进白血病细胞的存活、增殖和逃避免疫检测，从而积极塑造其微环境。在本综述中，我们讨论了CLL细胞如何破坏正常造血或免疫功能所需的生态位，并颠覆微环境中的正常细胞以支持肿瘤细胞的生长和存活。
相似文献
1
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.
Front Biosci (Schol Ed). 2012 Jan 1;4(1):61-73. doi: 10.2741/s251.
2
Regulation of hematopoietic and leukemic stem cells by the immune system.
Cell Death Differ. 2015 Feb;22(2):187-98. doi: 10.1038/cdd.2014.89. Epub 2014 Jul 4.
3
Restoration of in vitro hematopoiesis in B-chronic lymphocytic leukemia by antibodies to tumor necrosis factor.
Leuk Res. 1991;15(2-3):111-20. doi: 10.1016/0145-2126(91)90091-7.
4
The pathogenesis of chronic lymphocytic leukemia.
Annu Rev Pathol. 2014;9:103-18. doi: 10.1146/annurev-pathol-020712-163955. Epub 2013 Aug 26.
5
Immunobiology of chronic lymphocytic leukemia.
Hematol Oncol Clin North Am. 1990 Apr;4(2):405-29.
6
Bone marrow neoplastic niche in leukemia.
Hematology. 2014 Jun;19(4):232-8. doi: 10.1179/1607845413Y.0000000111. Epub 2013 Nov 25.
7
Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments.
Cells. 2021 Jan 22;10(2):217. doi: 10.3390/cells10020217.
8
IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing.
Autoimmunity. 1994;19(1):39-48. doi: 10.3109/08916939409008007.
9
Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.
Int J Hematol. 2015 Nov;102(5):528-35. doi: 10.1007/s12185-015-1740-1. Epub 2015 Feb 3.
10
Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Curr Mol Med. 2017;17(1):24-33. doi: 10.2174/1566524017666170220095838.
引用本文的文献
1
Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616-4.
2
The Impact of Targeted Therapies on Red Blood Cell Aggregation in Patients with Chronic Lymphocytic Leukemia Evaluated Using Software Image Flow Analysis.
Micromachines (Basel). 2025 Jan 15;16(1):95. doi: 10.3390/mi16010095.
3
Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.
Int J Mol Sci. 2022 Oct 22;23(21):12745. doi: 10.3390/ijms232112745.
4
Leukaemia: a model metastatic disease.
Nat Rev Cancer. 2021 Jul;21(7):461-475. doi: 10.1038/s41568-021-00355-z. Epub 2021 May 5.
5
Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia.
Sci Rep. 2021 Mar 4;11(1):5127. doi: 10.1038/s41598-021-84695-8.
6
Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis.
iScience. 2020 Dec 26;24(1):101994. doi: 10.1016/j.isci.2020.101994. eCollection 2021 Jan 22.
7
The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies.
Int J Mol Sci. 2020 May 11;21(9):3387. doi: 10.3390/ijms21093387.
8
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.
J Immunol. 2018 Sep 1;201(5):1570-1585. doi: 10.4049/jimmunol.1800591. Epub 2018 Aug 1.
9
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Am J Hematol. 2018 Nov;93(11):1311-1317. doi: 10.1002/ajh.25228. Epub 2018 Aug 31.
10
Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
Leukemia. 2018 Dec;32(12):2701-2705. doi: 10.1038/s41375-018-0164-3. Epub 2018 Jun 21.
本文引用的文献
1
B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18956-60. doi: 10.1073/pnas.1013420107. Epub 2010 Oct 18.
2
Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
Blood. 2010 Oct 21;116(16):2984-93. doi: 10.1182/blood-2010-02-269894. Epub 2010 Jul 6.
3
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Clin Cancer Res. 2010 Aug 15;16(16):4217-25. doi: 10.1158/1078-0432.CCR-10-0777. Epub 2010 Jul 2.
4
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.
5
Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
Exp Hematol. 2010 Sep;38(9):756-64, 764.e1-4. doi: 10.1016/j.exphem.2010.05.003. Epub 2010 May 19.
6
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.
7
CD44, a therapeutic target for metastasising tumours.
Eur J Cancer. 2010 May;46(7):1271-7. doi: 10.1016/j.ejca.2010.02.024. Epub 2010 Mar 19.
8
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
Leukemia. 2010 May;24(5):958-69. doi: 10.1038/leu.2010.36. Epub 2010 Mar 11.
9
Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.
Blood. 2010 May 13;115(19):3907-15. doi: 10.1182/blood-2009-09-244251. Epub 2010 Jan 28.
10
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.
Blood. 2010 Mar 4;115(9):1755-64. doi: 10.1182/blood-2009-09-242719. Epub 2009 Dec 17.
Zotero 插件